Close
Close

Squamous cell carcinoma of head and neck

Phase IIb trial comparing two concurrent cisplatin schedules in locally advanced head and neck cancer.
Related Articles

Phase IIb trial comparing two concurrent cisplatin schedules in locally advanced head and neck cancer.

South Asian J Cancer. 2017 Apr-Jun;6(2):64-68

Authors: Nair LM, Kumar RR, Thomachan KC, Rafi M, George PS, Krishna KMJ, Ramadas K

Abstract
BACKGROUND: Concurrent chemoradiation with 3 weekly cisplatin (100 mg/m(2)) is the standard of care for locally advanced head and neck cancer. However, this regimen has been shown to be associated with lesser compliance and higher toxicities. Hence, there is a need to explore alternative concurrent cisplatin regimens.
OBJECTIVES: The objective of this study was to compare the efficacy and toxicities of 3 weekly cisplatin (100 mg/m(2)) with weekly cisplatin (40 mg/m(2)) concurrently with radiation in patients with locally advanced head and neck cancer.
PATIENTS AND METHODS: This phase IIb trial randomized 56 patients with Stage III and IV squamous cell carcinoma of oropharynx, hypopharynx, and larynx to Arm A or Arm B. Arm A received cisplatin 100 mg/m(2) 3 weekly and Arm B received cisplatin 40 mg/m(2) weekly concurrently with radiation. The primary end point was disease-free survival (DFS) and secondary end points were overall survival (OS) and acute toxicity. DFS and OS were estimated using Kaplan-Meier method, and log-rank test was used to assess the difference in these distributions with respect to treatment.
RESULTS: The 2-year DFS in Arm A and Arm B was 64.5% and 52.8%, respectively (P = 0.67). The OS at 2 years was 71% and 61.1% in Arm A and Arm B, respectively (P = 0.61). There were no significant differences in acute hematological, renal, or mucosal toxicities between the two arms.
CONCLUSION: This study showed a nonsignificant improvement in DFS and OS in the 3 weekly cisplatin arm over the weekly arm with comparable toxicities. The trial is registered with Clinical Trial Registry of India (CTRI registration number: CTRI/2013/05/003703, URL-http://ctri.nic.in).

PMID: 28702409 [PubMed]

Videos
by Abidemi Uruejoma
11 views
by Abidemi Uruejoma
22 views
by Abidemi Uruejoma
18 views
by Abidemi Uruejoma
49 views
by Abidemi Uruejoma
64 views
Latest Research